ÂÜÀòÂÒÂ×

Kathryn Penkus Corzo is currently the Chief Operating Officer of bit.bio, an award-winning human synthetic biology company with a mission of coding cells to advance the wellbeing of humanity. Ms. Corzo is a highly regarded biotechnology executive with extensive experience in early and late drug development across multiple indications and platforms. Most recently she was a partner at Takeda Ventures, Inc. and previously Head of Oncology Cell Therapy Development at Takeda Pharmaceuticals, where she built capabilities and oversaw a cutting-edge oncology cell therapy portfolio including CAR-T, CAR-NK, iPSC and gamma-delta platforms. She also served on Takeda’s R&D Management Committee, was a member of Takeda’s Oncology Leadership Team and served on the board of directors for Maverick Therapeutics which was acquired by Takeda in March 2021.

Previously, Kathryn was Sanofi Genzyme’s Vice President R&D Myeloma Head where she led global registration programs to drug approvals in the US, EU and Japan. In addition, she held various R&D leadership roles at Hoffmann-La-Roche, Roche Molecular Systems, Eli Lilly and Syndax, contributing to the initial approval of 6 innovative cancer medicines and multiple indication expansions across the globe.